Huge impact of assumptions on indirect effects on the cost-effectiveness of routine infant vaccination with 7-valent conjugate vaccine (Prevnar®)

Vaccine

Volumn 28, Issue 12, 2010, Pages 2367-2369

  Rozenbaum, Mark H ^a   Hoek, Albert Jan van ^a   Hak, Eelko ^b   Postma, Maarten J ^a,b  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Cost effectiveness; Economics; Herd protection; PCV 7; Pneumococcal conjugate vaccine; Pneumococcus; Prevnar; S. pneumoniae; Serotype replacement; Vaccination

Indexed keywords

PNEUMOCOCCUS VACCINE;

ARTICLE; BACTEREMIA; COMMUNITY ACQUIRED PNEUMONIA; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFECT; DRUG EFFICACY; GENERAL PRACTITIONER; HEALTH CARE COST; HOSPITALIZATION; HUMAN; INCIDENCE; INFECTION RISK; NETHERLANDS; OTITIS MEDIA; OUTCOME ASSESSMENT; PNEUMOCOCCAL INFECTION; PNEUMOCOCCAL MENINGITIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; TREATMENT OUTCOME; VACCINATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; IMMUNITY, HERD; MALE; MIDDLE AGED; NETHERLANDS; PNEUMOCOCCAL VACCINES; VACCINATION; YOUNG ADULT;

EID: 77249128881     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.01.005     Document Type: Article

References (22)

1. Claes C., Reinert R.R., and von der Schulenburg J.M. Cost effectiveness analysis of heptavalent pneumococcal conjugate vaccine in Germany considering herd immunity effects. Eur J Health Econ 10 1 (2009 Feb) 25-38
2. Silfverdal S.A., Berg S., Hemlin C., and Jokinen I. The cost-burden of paediatric pneumococcal disease in Sweden and the potential cost-effectiveness of prevention using 7-valent pneumococcal vaccine. Vaccine 27 10 (2009 Mar 4) 1601-1608
3. Hubben G.A., Bos J.M., Glynn D.M., van der E.A., van A.L., and Postma M.J. Enhanced decision support for policy makers using a web interface to health-economic models--illustrated with a cost-effectiveness analysis of nation-wide infant vaccination with the 7-valent pneumococcal conjugate vaccine in the Netherlands. Vaccine 25 18 (2007 May 4) 3669-3678
4. McIntosh E.D., Conway P., Willingham J., Hollingsworth R., and Lloyd A. Pneumococcal pneumonia in the UK--how herd immunity affects the cost-effectiveness of 7-valent pneumococcal conjugate vaccine (PCV). Vaccine 23 14 (2005 Feb 25) 1739-1745
5. Whitney C.G., Farley M.M., Hadler J., et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 348 18 (2003 May 1) 1737-1746
6. Munoz-Almagro C., Jordan I., Gene A., Latorre C., Garcia-Garcia J.J., and Pallares R. Emergence of invasive pneumococcal disease caused by nonvaccine serotypes in the era of 7-valent conjugate vaccine. Clin Infect Dis 46 2 (2008 Jan 15) 174-182
7. Lepoutre A., Varon E., Georges S., Gutmann L., and Levy-Bruhl D. Impact of infant pneumococcal vaccination on invasive pneumococcal diseases in France, 2001-2006. Euro Surveill 13 35 (2008 Aug 28)
8. Health Protection Agency (HPA). Cumulative weekly number of reports of invasive pneumococcal disease in England and Wales by epidemiological year July-June. (accessed 09-07-2009). Health Protection Agency 2009Available from: URL: http://www.hpa.org.uk.
9. Bos J.M., Rumke H., Welte R., and Postma M.J. Epidemiologic impact and cost-effectiveness of universal infant vaccination with a 7-valent conjugated pneumococcal vaccine in the Netherlands. Clin Ther 25 10 (2003 Oct) 2614-2630
10. Jansen A.G.S.C., Rodenburg G.D., Greef S.C., et al. Invasive pneumococcal disease in the Netherlands: syndromes, outcome and potential vaccine benefits. Vaccine 27 (2009) 2394-2401
11. Black S., Shinefield H., Fireman B., et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children, Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 19 3 (2000 Mar) 187-195
12. Black S.B., Shinefield H.R., Ling S., et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr Infect Dis J 21 9 (2002 Sep) 810-815
13. Fireman B., Black S.B., Shinefield H.R., Lee J., Lewis E., and Ray P. Impact of the pneumococcal conjugate vaccine on otitis media. Pediatr Infect Dis J 22 1 (2003 Jan) 10-16
14. Nelson J.C., Jackson M., Yu O., et al. Impact of the introduction of pneumococcal conjugate vaccine on rates of community acquired pneumonia in children and adults. Vaccine 26 38 (2008 Sep 8) 4947-4954
15. Hsu H.E., Shutt K.A., Moore M.R., et al. Effect of pneumococcal conjugate vaccine on pneumococcal meningitis. N Engl J Med 360 3 (2009 Jan 15) 244-256
16. Lexau C.A., Lynfield R., Danila R., et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA 294 16 (2005 Oct 26) 2043-2051
17. Oostenbrink R., HA A.M., and Essink-Bot M.L. The EQ-5D and the Health Utilities Index for permanent sequelae after meningitis: a head-to-head comparison. J Clin Epidemiol 55 August (8) (2002) 791-799
18. Krabbe P.F., Hinderink J.B., and van den B.P. The effect of cochlear implant use in postlingually deaf adults. Int J Technol Assess Health Care 16 3 (2000) 864-873
19. Oostenbrink JB, Bouwmans CAM, Koopmanschap MA, Rutten FHH. Guidelines for costing research, methods and standardized prices for economic evaluations in health care. Health Care Insurance Board. 2004. Diemen, The Netherlands. Ref Type: Generic.
20. Council for Public Health and Health Care. Sensible and Sustainable Care (2006), Zoetermeer, The Netherlands
21. Bos J.M., and Postma M.J. Using pharmacoeconomics for policy making: is rational decision making enhanced by applying thresholds for cost-effectiveness?. Expert Rev Pharmacoeconomics Outcomes Res (2004) 247-250
22. Melegaro A., and Edmunds W.J. Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales. Vaccine 22 31-32 (2004 Oct 22) 4203-4214